Jones Trading Cuts Opus Genetics (NASDAQ:IRD) Price Target to $8.00

Opus Genetics (NASDAQ:IRD) had its price target decreased by equities researchers at Jones Trading from $9.00 to $8.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Opus Genetics in a research report on Tuesday.

Opus Genetics Stock Performance

IRD opened at $0.98 on Tuesday. Opus Genetics has a 12-month low of $0.81 and a 12-month high of $1.56. The company has a 50 day simple moving average of $1.08. The firm has a market capitalization of $31.46 million, a PE ratio of -0.90 and a beta of 0.28.

Opus Genetics (NASDAQ:IRD) last issued its quarterly earnings data on Monday, March 31st. The company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.93). Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%. The company had revenue of $3.40 million during the quarter, compared to the consensus estimate of $11.10 million. As a group, analysts forecast that Opus Genetics will post -1.22 earnings per share for the current year.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.